John Öhd, Modus Therapeutics' CEO, commented:” The third quarter has been marked by significant progress in our clinical pipeline, with a particular focus on our Phase 2a study for chronic kidney disease with anemia. The approval by the Italian regulatory authorities represents a strong opportunity to demonstrate sevuparin’s potential for this patient group. Our dedicated team is fully committed to advancing this study, with the ambition to deliver initial results during the first half of 2025. This progress has been further supported by secured bridge financing, which contributes to the maintained momentum in achieving our strategic milestones.”

The third quarter in figures

• The loss after tax amounted to TSEK 2 989 (3 093).
• The loss per share amounted to SEK 0,08 (0,19).
• The cash flow from current operations was negative in the amount of TSEK 3 971 (2 955).

The first 9-months in figures

• The loss after tax amounted to TSEK 10 831 (13 828).
• The loss per share amounted to SEK 0,30 (0,86).
• The cash flow from current operations was negative in the amount of TSEK 11 061 (13 557).

Important events during the third quarter

• Board Member Torsten Goesch passed away.
• Extraordinary General Meeting in Modus Therapeutics Holding AB held on September 27.
• Modus Therapeutics attended NLS Malmö, Sweden.
• Modus Therapeutics attended LSX, Copenhagen Denmark.

Important events after the end of the period

• Modus Therapeutics attended BioEurope Stockholm, Sweden.
• Modus Therapeutics receives a recruitment update for Malaria study.
• Modus Therapeutics receives approval to initiate a phase IIa clinical trial for chronic kidney disease (CKD).
• Modus Therapeutics secures access to bridge financing from Karolinska Development.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on November 20 at 14:00. Link to Interview: https://www.youtube.com/live/kp_Bs0okDyE?si=yfCFdJ8Z3vKaYKUu